Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological PregnanciesNucci M.a · Poon L.C.a · Demirdjian G.b · Darbouret B.b · Nicolaides K.H.a
aHarris Birthright Research Centre of Fetal Medicine, King's College Hospital, London, UK; bClinical Diagnostic Division, Thermo Fisher Scientific, Nîmes, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: To compare the maternal serum concentration of placental growth factor-1 (PlGF-1) and PlGF-2 at 11-13 weeks' gestation in normal pregnancies and in those complicated by preeclampsia (PE), delivery of small for gestational age (SGA) neonates and fetal trisomies 21, 18 and 13. Methods: Serum PlGF-1 and PlGF-2 were measured in 270 pathological pregnancies (PE, n = 80; SGA, n = 80; trisomy 21, n = 44; trisomy 18, n = 38; trisomy 13, n = 28) and 590 normal controls. The values were expressed as multiple of the median (MoM) after adjustment for maternal characteristics and corrected for adverse pregnancy outcomes and the median MoM values in each pathological pregnancy were compared to the normal group. Results: There were significant contributions to PlGF-1 and PlGF-2 from gestational age, smoking and racial origin. In addition, there were significant contributions to PlGF-1 from parity and method of conception. The median MoM of PlGF-1 and PlGF-2 was significantly decreased in PE (0.783 and 0.916 MoM), SGA (0.891 and 0.851 MoM), trisomy 21 (0.609 and 0.749 MoM), trisomy 18 (0.529 and 0.730 MoM) and trisomy 13 (0.373 and 0.699 MoM). Conclusions: In pathological pregnancies, except SGA, the decrease in serum PlGF-1 at 11-13 weeks' gestation is more marked than the decrease in PlGF-2.
© 2014 S. Karger AG, Basel
- De Falco S: The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44:1-9.
- Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
- Crispi F, Domínguez C, Llurba E, Martín-Gallán P, Cabero L, Gratacós E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195:201-207.
- Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-739.
- Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008;28:1110-1115.
- Spencer K, Liao AW, Ong CYT, Geerts L, Nicolaides KH: First-trimester maternal serum placenta growth factor (PlGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18. Prenat Diag 2001;21:718-722.
- Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol 2009;33:382-386.
- Cowans NJ, Stamatopoulou A, Spencer K: First-trimester maternal serum placental growth factor in trisomy 21 pregnancies. Prenat Diagn 2010;30:449-453.
- Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC: Modeling Down syndrome screening performance using first-trimester serum markers. Ultrasound Obstet Gynecol 2011;38:134-139.
- Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH: Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation. Fetal Diagn Ther 2012;31:87-93.
- Robinson HP, Fleming JE: A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975;182:702-710.
- Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15.
- Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
- Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012;32:156-165.
Mathis G: Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993;39:1953-1959.
- Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376-383.
- Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493-502.
- Robertson WB, Brosens I, Dixon G: Uteroplacental vascular pathology. Eur J Obstet Gynecol Reprod Biol 1975;5:47-65.
- Khong TY, De Wolf F, Robertson WB, Brosens IA: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-1059.
- Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997;18:657-665.
- Ahmed A, Dunk C, Ahmad S, Khaliq A: Regulation of placental vascular endothelial growth factor and placenta growth factor and soluble Flt-1 by oxygen - a review. Placenta 2000;21(suppl A):S16-S24.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.